Press releases
- Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
- Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
- Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
- Sobi publishes Annual and sustainability report for 2023
- Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024
More ▼
Key statistics
On Tuesday, Swedish Orphan Biovitrum AB (publ) (B6E:FRA) closed at 24.32, -8.09% below its 52-week high of 26.46, set on Feb 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.00 |
---|---|
High | 24.36 |
Low | 24.00 |
Bid | 23.90 |
Offer | 24.14 |
Previous close | 24.08 |
Average volume | 104.50 |
---|---|
Shares outstanding | 354.36m |
Free float | 195.56m |
P/E (TTM) | 46.11 |
Market cap | 101.13bn SEK |
EPS (TTM) | 6.19 SEK |
Data delayed at least 15 minutes, as of Apr 30 2024 10:45 BST.
More ▼